DIGESTIVE AND LIVER DISEASE is a prominent journal published by Elsevier Science Inc, dedicated to advancing the field of gastroenterology and hepatology. With an ISSN of 1590-8658 and an E-ISSN of 1878-3562, this journal has established itself as a significant resource within the academic community, especially considering its Q2 ranking in both gastroenterology and hepatology categories as of 2023. Spanning from 2000 to 2024, the journal presents a diverse array of peer-reviewed articles, clinical studies, and review papers that explore the latest advancements and research findings in digestive and liver diseases. The journal's robust impact, reflected in its Scopus rankings—40th out of 167 in gastroenterology and 28th out of 82 in hepatology—highlights its critical role in shaping practices and understanding in these vital areas of medicine. With open access options available, DIGESTIVE AND LIVER DISEASE aims to make high-quality research accessible to a wider audience, thereby encouraging collaboration and innovation. Researchers, healthcare professionals, and students alike will find valuable insights into the complex mechanisms, diagnostics, and therapeutic strategies pertinent to digestive and liver health.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

The Journal of Gastrointestinal and Liver Diseases, published by MEDICAL UNIV PRESS in Romania, serves as a pivotal platform for the dissemination of significant research in the fields of gastroenterology and hepatology. Established in 2006, this journal has evolved over the years, currently holding a Q3 rank in Gastroenterology and a Q2 rank in Medicine (miscellaneous), reflecting its commitment to high-quality scholarship and impactful contributions to medical science.

With an ISSN of 1841-8724 and an E-ISSN of 1842-1121, the journal engages a diverse readership of researchers, clinicians, and students passionate about advancing knowledge in gastrointestinal and liver health. While it currently does not operate under an open access model, the journal remains a vital resource for those seeking to stay updated on the latest developments and emerging trends in the field. As it converges towards a broader impact, projected through its coverage until 2024, the Journal of Gastrointestinal and Liver Diseases continues to contribute to the academic landscape, encouraging innovation and comprehensive understanding in digestive health.

The Journal of Clinical and Experimental Hepatology, published by Elsevier - Division Reed Elsevier India Pvt Ltd, is a premier platform dedicated to advancing the field of hepatology. With an ISSN of 0973-6883 and an E-ISSN of 2213-3453, this journal has gained recognition for its impactful contributions to both clinical practice and scientific research in the domain of liver health. Ranking in the Q2 quartile for Hepatology in 2023 and positioned at 33rd out of 82 in Scopus’s Hepatology category, it reflects a robust impact factor and a commitment to publishing high-quality, peer-reviewed articles. Researchers, clinicians, and students can engage with a wealth of open-access content covering the latest advancements, challenges, and insights in hepatology, as the journal aims to disseminate knowledge from 2011 through 2025. Join the community of experts as we explore critical developments in the understanding and treatment of liver diseases.

Clinical and Molecular Hepatology, published by the Korean Association for the Study of Liver, stands at the forefront of hepatology, offering a significant platform for research and innovation in liver diseases. Established in 1995 as an open access journal, it aims to disseminate high-quality research that spans the fields of hepatology, molecular biology, and medicine. With an impressive impact factor ranking it in the Q1 category for 2023 in both Hepatology and Molecular Biology, the journal facilitates a rich exchange of knowledge among professionals, researchers, and students globally. With its dedicated coverage from 2012 to 2024 and exceptional Scopus rankings placing it within the top 10% of journals in its field, Clinical and Molecular Hepatology is an indispensable resource for advancing the understanding and treatment of liver conditions. Located in Seoul, South Korea, the journal emphasizes rigorous peer review and is committed to enhancing clinical practice and molecular research, making it an ideal venue for groundbreaking studies in liver health.

Welcome to the JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, an esteemed publication in the field of gastroenterology and hepatology, proudly published by WILEY. Established in 1986, this journal serves as a crucial platform for researchers, healthcare professionals, and students, presenting groundbreaking research and comprehensive reviews that drive advances in understanding and treating gastrointestinal and liver diseases. With a strong reputation evidenced by its Q1 ranking in gastroenterology and Q2 ranking in hepatology, this journal ranks impressively in the Scopus metrics - positioned at #22 out of 167 in gastroenterology and #21 out of 82 in hepatology, reflecting its contribution to scholarly excellence. Although it does not offer open access options, the journal’s rich archive and diverse topics make it indispensable for those dedicated to improving patient outcomes in these critical areas of medicine. Whether you are a seasoned researcher or an aspiring medical professional, engaging with this journal will keep you at the forefront of the latest developments and emerging trends in gastroenterology and hepatology research.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

Hepatology Forum is an esteemed journal dedicated to disseminating cutting-edge research and insights in the fields of gastroenterology and hepatology. Published by KARE PUBL in Turkey, this journal serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to advance their knowledge and practices related to liver diseases and gastrointestinal disorders. With an ISSN of 1307-5888 and an E-ISSN of 2757-7392, it features peer-reviewed articles that encompass a wide range of topics from basic research to clinical applications. Although categorized in the Q3 quartile for both gastroenterology and hepatology in 2023, Hepatology Forum continues to show significant potential for growth and impact, as evidenced by its Scopus rankings. Through its commitment to open scientific exchange, the journal not only facilitates the sharing of innovative methodologies and findings but also fosters networking among professionals in the field. As it converges through the years from 2020 to 2024, Hepatology Forum remains an important resource for the advancement of liver health and diseases, appealing to both established experts and emerging scholars alike.

Canadian Liver Journal, published by University of Toronto Press Inc., offers a dedicated platform for the dissemination of cutting-edge research in the field of Hepatology. With an E-ISSN of 2561-4444, this journal plays a pivotal role in advancing knowledge related to liver diseases and therapies, currently ranked in the 3rd quartile (Q3) for the 2023 category in Hepatology—a reflection of its growing influence in the biomedical research community. The journal, which has been in circulation since 2018 and sets its sights on contributing valuable insights until 2024, aims to engage researchers, clinicians, and students alike by providing a rigorous peer-reviewed environment for sharing findings, case studies, and reviews pertinent to liver health. Through its commitment to excellence and scholarly impact, the Canadian Liver Journal serves as an essential resource for those dedicated to combating liver diseases and enhancing patient care.

JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.